Apigenin inhibits TGF-β-induced VEGF expression in human prostate carcinoma cells via a Smad2/3- and Src-dependent mechanism

The Emerging Role of Vascular Endothelial Growth Factor (VEGF) in Vascular Homeostasis: Lessons from Recent Trials with Anti-VEGF Drugs

(2011) Shivshankar Thanigaimani et al.   Current Vascular Pharmacology

Blockade of transforming growth factor-beta (TGFβ) signaling inhibits osteoblastic tumorigenesis by a novel human prostate cancer cell line

(2011) Sweta Mishra et al.   PROSTATE

Apigenin: A Promising Molecule for Cancer Prevention

(2010) Sanjeev Shukla et al.   PHARMACEUTICAL RESEARCH

The Chemopreventive Bioflavonoid Apigenin Inhibits Prostate Cancer Cell Motility through the Focal Adhesion Kinase/Src Signaling Mechanism

(2009) C. A. Franzen et al.   Cancer Prevention Research

Targeting TGF-β in prostate cancer: therapeutic possibilities during tumor progression

(2009) Elisabeth Jones et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Prospective Study of Prostate Tumor Angiogenesis and Cancer-Specific Mortality in the Health Professionals Follow-Up Study

(2009) Lorelei A. Mucci et al.   JOURNAL OF CLINICAL ONCOLOGY

Tumoral Angiogenesis: Review of the Literature

(2008) Parham Khosravi Shahi et al.   CANCER INVESTIGATION

Inhibition of HIF-1 alpha and VEGF expression by the chemopreventive bioflavonoid apigenin is accompanied by Akt inhibition in human prostate carcinoma PC3-M cells

(2008) Salida Mirzoeva et al.   MOLECULAR CARCINOGENESIS